JP2023506017A5 - - Google Patents
Info
- Publication number
- JP2023506017A5 JP2023506017A5 JP2022535811A JP2022535811A JP2023506017A5 JP 2023506017 A5 JP2023506017 A5 JP 2023506017A5 JP 2022535811 A JP2022535811 A JP 2022535811A JP 2022535811 A JP2022535811 A JP 2022535811A JP 2023506017 A5 JP2023506017 A5 JP 2023506017A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding site
- seq
- amino acid
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946931P | 2019-12-11 | 2019-12-11 | |
| US62/946,931 | 2019-12-11 | ||
| PCT/US2020/064706 WO2021119551A1 (en) | 2019-12-11 | 2020-12-11 | Anti-cd19 antibodies and multi-specific binding proteins |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023506017A JP2023506017A (ja) | 2023-02-14 |
| JP2023506017A5 true JP2023506017A5 (https=) | 2023-12-15 |
| JP7780434B2 JP7780434B2 (ja) | 2025-12-04 |
Family
ID=76329102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022535811A Active JP7780434B2 (ja) | 2019-12-11 | 2020-12-11 | 抗ｃｄ１９抗体および多重特異性結合タンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12428480B2 (https=) |
| EP (1) | EP4073122A4 (https=) |
| JP (1) | JP7780434B2 (https=) |
| CN (1) | CN115916818A (https=) |
| AU (1) | AU2020403273A1 (https=) |
| CA (1) | CA3161283A1 (https=) |
| IL (1) | IL293725A (https=) |
| WO (1) | WO2021119551A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL293725A (en) | 2019-12-11 | 2022-08-01 | Cullinan Oncology Inc | Anti-cd19 antibodies and multispecific binding proteins |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| KR20260020379A (ko) * | 2023-04-07 | 2026-02-11 | 쿨리난 테라퓨틱스, 인코포레이티드 | 다중특이적 결합 단백질의 사용 방법 |
| WO2025165980A1 (en) * | 2024-01-31 | 2025-08-07 | Cullinan Therapeutics, Inc. | Therapies for autoimmune disorders |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US10000574B2 (en) | 2003-11-28 | 2018-06-19 | Amgen Research (Munich) Gmbh | Compositions comprising polypeptides |
| CN101128487B (zh) | 2004-12-02 | 2012-10-10 | 杜门蒂斯有限公司 | 靶向血清白蛋白和glp-1或pyy的双特异性结构域抗体 |
| HRP20150175T1 (en) | 2005-12-16 | 2015-03-27 | Amgen Research (Munich) Gmbh | Means and methods for the treatment of tumorous diseases |
| DK2211904T3 (en) | 2007-10-19 | 2016-10-24 | Seattle Genetics Inc | Cd19-binding agents and uses thereof |
| EP2673297A2 (en) | 2011-02-11 | 2013-12-18 | Zyngenia, Inc. | Monovalent and multivalent multispecific complexes and uses thereof |
| US9527925B2 (en) | 2011-04-01 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Bispecific binding molecules binding to VEGF and ANG2 |
| WO2013013700A1 (en) | 2011-07-22 | 2013-01-31 | Affimed Therapeutics Ag | Multivalent antigen-binding fv molecule |
| PE20141522A1 (es) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | Proteinas y peptidos modificados |
| WO2014012082A2 (en) | 2012-07-13 | 2014-01-16 | Zymeworks Inc. | Multivalent heteromultimer scaffold design an constructs |
| AU2013289883B2 (en) | 2012-07-13 | 2018-11-01 | Zymeworks Bc Inc. | Bispecific asymmetric heterodimers comprising anti-CD3 constructs |
| JP2017512814A (ja) | 2014-04-07 | 2017-05-25 | シアトル ジェネティックス， インコーポレイテッド | 抗ｃｄ１９抗体および抗体−薬物結合体のための安定な製剤 |
| UY36245A (es) | 2014-07-31 | 2016-01-29 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| CN120988137A (zh) | 2015-01-23 | 2025-11-21 | 赛诺菲 | 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体 |
| CN107406507A (zh) | 2015-02-12 | 2017-11-28 | 西雅图基因公司 | 使用cd19‑adc和长春新碱的组合疗法 |
| CN114920848B (zh) | 2015-05-13 | 2024-10-11 | 埃博灵克斯股份有限公司 | 基于cd3反应性的t细胞募集多肽 |
| US9708412B2 (en) | 2015-05-21 | 2017-07-18 | Harpoon Therapeutics, Inc. | Trispecific binding proteins and methods of use |
| EP3322735A4 (en) | 2015-07-15 | 2019-03-13 | Zymeworks Inc. | ACTIVE CONJUGATED BIS-SPECIFIC ANTIGEN-BONDING CONSTRUCTS |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| WO2017055314A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific anti-cd19xcd3 t cell activating antigen binding molecules |
| AU2016330807B2 (en) * | 2015-10-02 | 2023-08-10 | F. Hoffmann-La Roche Ag | Anti-human CD19 antibodies with high affinity |
| AU2016357460B2 (en) * | 2015-11-18 | 2023-07-27 | Ablynx Nv | Improved serum albumin binders |
| CN105399832A (zh) | 2015-12-07 | 2016-03-16 | 四川大学 | 一种无标签单链型人源双特异性抗体及其用途 |
| KR20180133442A (ko) | 2016-04-13 | 2018-12-14 | 비비아 바이오테크 에스.엘. | 생체외 bite 활성화된 t 세포 |
| EP3243836A1 (en) | 2016-05-11 | 2017-11-15 | F. Hoffmann-La Roche AG | C-terminally fused tnf family ligand trimer-containing antigen binding molecules |
| WO2018098356A1 (en) | 2016-11-23 | 2018-05-31 | Harpoon Therapeutics, Inc. | Psma targeting trispecific proteins and methods of use |
| FR3068662B1 (fr) | 2017-07-04 | 2019-08-30 | Le Joint Francais Snc | Passe-cloison pour un organe destine a traverser une cloison |
| WO2019077062A1 (en) | 2017-10-18 | 2019-04-25 | Vivia Biotech, S.L. | C-CELLS ACTIVATED BY BIT |
| JP7383704B2 (ja) * | 2018-06-07 | 2023-11-20 | カリナン オンコロジー インコーポレイテッド | 多重特異性結合タンパク質およびその使用方法 |
| US10815311B2 (en) * | 2018-09-25 | 2020-10-27 | Harpoon Therapeutics, Inc. | DLL3 binding proteins and methods of use |
| IL293725A (en) | 2019-12-11 | 2022-08-01 | Cullinan Oncology Inc | Anti-cd19 antibodies and multispecific binding proteins |
| IL293780A (en) | 2019-12-11 | 2022-08-01 | Cullinan Man Inc | Anti-serum albumin antibodies |
-
2020
- 2020-12-11 IL IL293725A patent/IL293725A/en unknown
- 2020-12-11 CN CN202080095894.0A patent/CN115916818A/zh active Pending
- 2020-12-11 EP EP20899414.5A patent/EP4073122A4/en active Pending
- 2020-12-11 JP JP2022535811A patent/JP7780434B2/ja active Active
- 2020-12-11 US US17/784,988 patent/US12428480B2/en active Active
- 2020-12-11 WO PCT/US2020/064706 patent/WO2021119551A1/en not_active Ceased
- 2020-12-11 CA CA3161283A patent/CA3161283A1/en active Pending
- 2020-12-11 AU AU2020403273A patent/AU2020403273A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2025111463A5 (https=) | ||
| JP2023506017A5 (https=) | ||
| JP2024038003A5 (https=) | ||
| JP2022177090A5 (https=) | ||
| JP2024167313A5 (https=) | ||
| RU2013125306A (ru) | Связывающие протеины, специфичные по отношению к инсулин-подобным факторам роста, и их использование | |
| JP2023506834A5 (https=) | ||
| JP2020536109A5 (https=) | ||
| CN116396386A (zh) | Cd3抗体及其药物用途 | |
| JP2022533538A5 (https=) | ||
| RU2012112829A (ru) | Анти-gitr-антитела | |
| RU2020130795A (ru) | Нейтрализующие антитела к env вич-1 и их применение | |
| AR069062A1 (es) | Anticuerpo anti-hepcidina | |
| RU2018120695A (ru) | Связывающие молекулы, специфичные в отношении asct2, и их применения | |
| JP2024506315A5 (https=) | ||
| JP2025038088A5 (https=) | ||
| JP2020515277A5 (https=) | ||
| JP2024540148A5 (https=) | ||
| CN111712521A (zh) | Cd38蛋白抗体及其应用 | |
| JP2021512652A5 (https=) | ||
| JP2023545183A5 (https=) | ||
| JP2024516098A5 (https=) | ||
| JP2017511152A5 (https=) | ||
| CN107488230A (zh) | 一种抗人CD79a胞外端蛋白的抗体、编码基因及应用 | |
| IL278323B1 (en) | Antibodies directed against glycoprotein IV |